Study details
Enrolling now
Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
University of Colorado, Denver
NCT IDNCT01773278ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
100
Study length
about 17 years
Ages
≤65
Locations
1 site in CO
About this study
This trial is testing a treatment with cholesterol and antioxidants for people with Smith-Lemli-Opitz Syndrome. Participants will have regular checkups, blood tests, and eye exams to monitor their health.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Antioxidants
- 2.Take Cholesterol
PhasePhase 2
DrugCholesterol
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low4%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
Biological Macromolecular Activity